Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773668 | 0.80 | PTPN1 (0.40) | PTPN1PDE4BALDH1A1POLB | |
| SCHEMBL5797594 | 0.76 | PDE4B (0.37) | PTPN1PDE4BCREBBPMEN1KMT2A | |
| SCHEMBL6908438 | 0.75 | GAA (0.41) | PTPN1PDE4BCREBBPKDM4EMEN1 | |
| SCHEMBL29311949 | 0.74 | PDE4B (0.38) | PTPN1PDE4B | |
| SCHEMBL2968461 | 0.73 | ALDH1A1 (0.50) | ALDH1A1HPGDMAPK1 | |
| SCHEMBL30065877 | 0.73 | ALDH1A1 (0.50) | ALDH1A1HPGDMAPK1 | |
| SCHEMBL5618972 | 0.73 | MEN1 (0.43) | PTPN1PDE4BCREBBPMEN1KMT2A | |
| SCHEMBL4119366 | 0.73 | MAOB (0.40) | PTPN1CREBBPMEN1KMT2AALDH1A1 | |
| SCHEMBL5619093 | 0.73 | PDE4B (0.47) | PTPN1PDE4BCREBBPKDM4EMEN1 | |
| SCHEMBL4125128 | 0.72 | PTPN1 (0.45) | PTPN1PDE4BCREBBPKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078541-B2 | Benzofuran derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063975-A1 | Benzofuran derivatives | EDISON PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063975-A1 | Benzofuran derivatives | NDUFAB1, AIFM1, NDUFAF1 | PTPN1 4821/4885PDE4B 2387/4885CREBBP 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.